Metsera and Maze Therapeutics priced their Nasdaq IPOs, raising $275M and $140M respectively. Both companies backed by ARCH ...

(Reuters) -Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care ...

NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog ...

With the Fed's two-day FOMC meeting concluding yesterday, no offerings were priced in the IG primary, leaving weekly IG issuance so far to date at US$11.67bn, according to IFR data. But that will ...

Metsera, Inc MTSR IPO will take place January, 31 on the NASDAQ exchange under the ticker MTSR. The company is offering shares at an expected price between $15.00 and $17.00 per share with an insider ...

This article highlights recent developments in healthcare, including the U.S. FDA's approval of Alzheimer's and diabetes ...

Metsera, Inc. aims to raise $275 million in an IPO to fund its clinical-stage biopharma programs targeting obesity and ...

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

The Fed begins its two-day FOMC meeting, which will conclude at 2:00pm on Wednesday, followed by a Fed rate announcement and a press conference held by Fed Chairman Jerome Powell. The CME's FedWatch ...

The biotech IPO landscape gains momentum in 2025 as Aurion Biotech, Maze Therapeutics, and Metsera file for offerings. Aurion focuses on regenerative therapies, Maze advances precision medicines for ...